SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter.
On a per-share basis, the San Diego-based company said it had a loss of 20 cents.
The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 22 cents per share.
For the year, the company reported a loss of $46.4 million, or 82 cents per share.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.